(Q37074097)

18 August 2017

1 reference

title

Use of genetic and nongenetic factors in warfarin dosing algorithms (English)

1 reference

18 August 2017

0 references

1 reference

Alan H B Wu

1

1 reference

PubMed ID

18240910

18 August 2017

language of work or name

1 reference

1 July 2007

1 reference

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

851-861

1 reference

18 August 2017

7

1 reference

Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?

18 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

National surveillance of emergency department visits for outpatient adverse drug events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Aging and the anticoagulant response to warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Anticoagulant use in patients with chronic renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Cytochrome P4502C9 activity in end‐stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

The influence of ethnicity on warfarin dosage requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Pharmacogenomics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Population variation in VKORC1 haplotype structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

APOE genotype makes a small contribution to warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.851

21 January 2018

Identifiers

DOI

10.2217/14622416.8.7.851

1 reference

18 August 2017

1 reference

PubMed ID

18240910